Androgen Antagonists Concept

subject area of

• A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer  Journal Articles
• A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design  Journal Articles
• A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow  Journal Articles
• Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial  Journal Articles
• Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial  Journal Articles
• Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621  Journal Articles
• Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase  Journal Articles
• Androgen‐dependent regulation of medium and long chain fatty acids uptake in prostate cancer  Journal Articles
• Assessment methods and management of hypersexuality and paraphilic disorders  Journal Articles
• Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis  Journal Articles
• Attenuation of Resting but Not Load-Mediated Protein Synthesis in Prostate Cancer Patients on Androgen Deprivation  Journal Articles
• Behavioral and physiological responses of a wild teleost fish to cortisol and androgen manipulation during parental care  Journal Articles
• Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601  Journal Articles
• Bisphosphonate prescriptions in men with androgen deprivation therapy use.  Journal Articles
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer  Journal Articles
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer  Journal Articles
• Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial  Journal Articles
• Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer  Journal Articles
• Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease  Journal Articles
• Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study  Journal Articles
• Cardiovascular Risk in Prostate Cancer.  Journal Articles
• Cardiovascular effects of androgen depletion and replacement therapy  Journal Articles
• Cardiovascular risk in ADT recipients: does the type of ADT matter?  Journal Articles
• Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms  Journal Articles
• Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D  Journal Articles
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.  Journal Articles
• Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis  Journal Articles
• Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada  Journal Articles
• Current management of advanced and castration resistant prostate cancer.  Journal Articles
• Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.  Journal Articles
• Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases  Journal Articles
• Distribution of nitroreductive activity toward nilutamide in rat  Journal Articles
• Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910  Journal Articles
• Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial  Journal Articles
• Editorial Comment  Journal Articles
• Effects of a model androgen (methyl testosterone) and a model anti-androgen (cyproterone acetate) on reproductive endocrine endpoints in a short-term adult mummichog (Fundulus heteroclitus) bioassay  Journal Articles
• Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic  Journal Articles
• Fire Fetishism, Diagnostic and Clinical Implications: A Review of Two Cases^*  Journal Articles
• GU radiation oncologists consensus on bone loss from androgen deprivation.  Journal Articles
• Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial  Journal Articles
• GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model1Contributed equally and share first authorship.  Journal Articles
• Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer  Journal Articles
• Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: A mechanistic model supporting prevention strategies  Journal Articles
• Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy  Journal Articles
• Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.  Journal Articles
• Long-term Followup of a Randomized Trial of 0 Versus 3 Months of Neoadjuvant Androgen Ablation Before Radical Prostatectomy  Journal Articles
• Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy  Journal Articles
• Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?  Journal Articles
• Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.  Journal Articles
• Metabolism of nilutamide in rat lung  Journal Articles
• New-onset psychosis following androgen deprivation therapy for prostate cancer.  Journal Articles
• Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline  Journal Articles
• Osteoporosis Associated with the Treatment of Paraphilias: A Clinical Review of Seven Case Reports  Conferences
• Oxidative Stress and Bioindicators of Reproductive Function in Pulp and Paper Mill Effluent Exposed White Sucker  Journal Articles
• PREDICTORS OF PATHOLOGICAL STAGE BEFORE NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY AND RADICAL PROSTATECTOMY  Journal Articles
• Pharmacologic Treatment of Paraphilias  Journal Articles
• Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials  Journal Articles
• Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials  Journal Articles
• Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model  Journal Articles
• Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT  Journal Articles
• Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia  Journal Articles
• Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).  Journal Articles
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer  Journal Articles
• Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy  Journal Articles
• Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer  Journal Articles
• Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer  Journal Articles
• Reduction of Nilutamide by NO Synthases:  Implications for the Adverse Effects of This Nitroaromatic Antiandrogen Drug  Journal Articles
• Reply by Authors  Journal Articles
• Salvage radiotherapy following HiFU: An institutional series and literature review  Journal Articles
• Sexually aggressive men.  Journal Articles
• Synthesis and Structure–Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide  Journal Articles
• Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer  Journal Articles
• Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial  Journal Articles
• The Cardiologist's Role in the Management of Patients with a Genitourinary Cancer.  Journal Articles
• The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments  Journal Articles
• The Neurobiology, Neuropharmacology, and Pharmacological Treatment of the Paraphilias and Compulsive Sexual Behaviour  Journal Articles
• The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphilias  Journal Articles
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial  Journal Articles
• The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer  Journal Articles
• The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol  Journal Articles
• The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.  Journal Articles
• Therapeutic options in advanced prostate cancer: Present and future  Journal Articles
• Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme  Journal Articles
• Treatment of advanced cancer of the prostate.  Journal Articles
• Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?  Journal Articles